CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastroesophageal cancers.
  
  LEARNING OBJECTIVES

  • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to personalize the selection of first-line therapy for locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
  • Describe the published research data with approved and investigational anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies in the management of gastric, GEJ and esophageal cancers, and consider the current and future placement of these strategies in treatment algorithms.
  • Optimally incorporate available therapeutic agents and regimens into the care of patients with HER2-negative metastatic gastric, GEJ or esophageal cancer who have experienced disease progression on front-line chemotherapy or chemoimmunotherapy.
  • Appraise clinical trial findings supporting the use of adjuvant anti-PD-1 antibody therapy for patients with resected esophageal/GEJ cancer who have received neoadjuvant chemoradiation therapy and have residual pathologic disease, and discern the clinical applicability of this treatment strategy.
  • Recall available data with novel HER2-targeted agents and strategies for patients with newly diagnosed or previously treated HER2-overexpressing gastric or GEJ cancer, and identify candidates who may be appropriate for these approaches.
  • Recognize common and rare side effects associated with approved and investigational agents used in the care of patients with gastroesophageal cancers, and apply this information to develop appropriate and effective supportive management plans.
  • Review the rationale for, available data with and ongoing research evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY & MODERATOR — The following faculty and moderator reported relevant financial relationships with ineligible entities:
  
  FACULTY
  
  Yelena Y Janjigian, MD
  Associate Professor
  Chief of Gastrointestinal Oncology Service
  Department of Medicine
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Imugene, Lilly, Merck, Merck Serono, MJH Life Sciences, Pfizer Inc, Rgenix, Seagen Inc, Zymeworks Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Cycle for Survival, Fred's Team, Genentech, a member of the Roche Group, Lilly, Merck, National Cancer Institute, Rgenix, US Department of Defense; Stock Options: Rgenix.
  
  Eric Van Cutsem, MD, PhD
  Professor of Medicine
  Digestive Oncology
  University Hospitals Leuven
  Leuven, Belgium
  
  Advisory Committee: AbbVie Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biocartis, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, GlaxoSmithKline, Halozyme Inc, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, Pierre Fabre, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation, TRIGR (trial), Zymeworks Inc; Research Grants to Institution: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Novartis, Roche Laboratories Inc, Servier Pharmaceuticals LLC.
  
  Harry H Yoon, MD
  Associate Professor of Oncology
  Co-Chair, Gastroesophageal Cancer Disease Group
  Mayo Clinic Comprehensive Cancer Center
  Rochester, Minnesota
  
  Advisory Committee: ALX Oncology, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, MacroGenics Inc, Merck, Novartis, OncXerna Therapeutics Inc, Zymeworks Inc; Contracted Research: BeiGene Ltd, Bristol-Myers Squibb Company, CARsgen Therapeutics, Merck, Sumitomo Dainippon Pharma Oncology Inc.
  
  Moderator
  
  Samuel J Klempner, MD
  Associate Professor
  Massachusetts General Hospital
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Merck, Natera Inc, Pieris Pharmaceuticals Inc; Consulting Agreement: Lilly; Contracted Research (to Institution): BeiGene Ltd (clinical trial); Ownership Interest: Turning Point Therapeutics Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Coherus BioSciences, Daiichi Sankyo Inc and Lilly.
  
  Release date: February 2022
  Expiration date: February 2023